News and Announcements
Proteomics March Update: PromarkerD Progress, Indian Biotech Market Expansion & Solid Quarter Results
- Published April 26, 2016 11:48AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th April 2016, ASX Announcement
Life sciences company Proteomics International Laboratories Ltd (ASX:PIQ) (the Company, PILL) is pleased to provide the following update on its business activities for the three month period to 31 March 2016.
Highlights
- PromarkerD progress: 500 patient follow-up validation study underway to further validate PromarkerD’s initial ground-breaking results.
- IVD test kit for PromarkerD: Assessing development program to produce a clinical pathology In Vitro Diagnostic (IVD) test kit for PromarkerD.
- Therapeutic Drug Discovery Program: to discover new analgesic and antibiotics drug compounds.
- Analytical Services operations: Solid quarter-on-quarter results.
- Business Development: Company expands operations in massive Indian biotech market.
The March quarter delivered another period of sound performance for PILL. During the quarter, it embarked on a number of programs utilising its proprietary, disruptive technology platform. This included a development program, to produce a standard clinical pathology In Vitro Diagnostic (IVD) test kit for PromarkerD.
To view the full article, please click on the button below.
Company Updates
Backed By Leading Investment Groups and Family Offices
